Application of lactobacillus paracasei RBB-10, composition and microbial preparation

Through the microbial composition of C. paracetamol RBB-10, S. cerevisiae S-16 and A. Pasteuris, combined with the combination technology of materials such as sodium alginate, a stable microsphere structure was formed, which solved the side effects of existing antioxidants. The problem has significantly improved antioxidant capacity and immunity, and improved the symptoms of aging-related diseases.

CN118948900APending Publication Date: 2024-11-15HANGZHOU JUNWU XIYAN BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202411436459.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-15
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing antioxidants are prone to side effects after oral administration, such as high-iron erythrocyte anemia, diarrhea, hypermotor peristalsis and gastrointestinal bleeding, and have not effectively solved the problems of aging-related diseases such as hypertension, type II diabetes and Alzheimer's disease. .

Method used

Using microbial compositions of C. paracetamol RBB-10, S. cerevisiae S-16 and A. Pasteuris, the combination of sodium alginate, collagen and other auxiliary materials is used to form a stable microsphere structure and improve the microbial composition. The loading and stability of the product enhances antioxidant activity, and improves biocompatibility and embedding efficiency through the coating of the glutathione-fucosan-terminal carboxypolyamide complex.

Benefits of technology

It significantly improves antioxidant ability, enhances the body's immunity, improves the survival rate and sustained release effect of microorganisms in the intestines, reduces the free radical level in the serum, and increases the activity of glutathione peroxidase in the serum, significantly Improves symptoms of aging-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948900A_ABST
    Figure CN118948900A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of microbial engineering, and particularly discloses application of lactobacillus paracasei RBB-10, a microbial composition, a microbial preparation and a preparation method of the microbial preparation. The lactobacillus paracasei RBB-10 is applied to any one of the following items (1) to (5): (1) preparing an anti-oxidation product, (2) preparing an anti-oxidation product, (3) preparing an anti-oxidation product, (4) preparing an anti-oxidation product, (5) preparing an anti-oxidation product, (5) preparing an anti-oxidation product and (6) preparing an anti-oxidation product. (2) preparing an anti-aging product; (3) preparing a product for repairing colonic mucosa; (4) preparing a product for inhibiting the growth of Helicobacter (Helicobacter) in the intestinal tract; and (5) preparing a product for promoting the growth of the unclassified genus of the murine bacillus, the genus of the murine bacillus and / or the genus of the bifidobacterium in the intestinal tract. The invention also discloses a preparation method of the product for promoting the growth of the unclassified genus of the murine bacillus, the genus of the murine bacillus and / or the genus of the bifidobacterium in the intestinal tract.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microbial engineering, and in particular to an application of Lactobacillus paracasei RBB-10, a microbial composition, a microbial preparation and a preparation method thereof. Background Art

[0002] As human life span increases, impaired immune response, malnutrition, metabolic disorders, negligence and drug abuse will lead to aging, hypertension, type II diabetes, atherosclerosis and Alzheimer's disease. Oral administration of compound antioxidants often causes iron-rich anemia, diarrhea, intestinal hypermotility, abdominal pain and gastrointestinal bleeding, and may cause side effects such as hyperuricemia.

[0003] Lactobacillus paracasei, also known as Lactobacillus paracasei, is a facultative anaerobic pleomorphic bacillus. As one of the bacteria species that can be used in food production and processing, it is safe and non-toxic to eat. It can promote intestinal peristalsis, maintain the balance of intestinal flora, and thus enhance the body's resistance.

[0004] Lactobacillus paracasei is beneficial to enhancing human physique and can be used as a research hotspot with great potential. It is also being used to make probiotic preparations suitable for the body.

[0005] Due to the diversity of sources of Lactobacillus paracasei, it has genetic diversity and functional diversity. Although the functions and applications of a few Lactobacillus paracasei have been developed, their potential efficacy is still far from being fully and deeply explored, and their antioxidant and anti-aging effects have not yet been developed. Summary of the invention

[0006] The purpose of the present invention is to solve the shortcomings in the prior art and to propose an application of Lactobacillus paracasei RBB-10, a microbial composition, a microbial preparation and a preparation method thereof.

[0007] Lactobacillus paracasei ( Lacticaseibacillus paracasei )RBB-10 is used in any of the following (1)-(5): (1) Preparation of antioxidant products; (2) Preparation of anti-aging products; (3) preparing products for repairing colon mucosa; (4) Preparation of Helicobacter spp. Helicobacter ) products grown; (5) Preparation of unclassified members of the family Rhabditiaceae that promote intestinal Unclassified Muribaculaceae ), Rhabditis spp. Muribaculum ) or / and Bifidobacterium spp. ( Bifidobacterium ) products grown.

[0008] Preferably, Lactobacillus paracasei RBB-10 is deposited in the General Microbiological Center of China National Microbiological Culture Collection Administration with a deposit number of CGMCC NO.30557.

[0009] Preferably, the product is a microbial preparation, a health food or a medicine.

[0010] A microbial composition comprises: the Lactobacillus paracasei RBB-10.

[0011] Preferably, the above-mentioned microbial composition further comprises: Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) S-16, Acetobacter pasteurianus ( Acetobacter pasteurianus ).

[0012] Preferably, in the above microbial composition, the viable count of Lactobacillus paracasei RBB-10 is 1-5×10 9 cfu / g, the number of viable bacteria of Saccharomyces cerevisiae S-16 is 1-3×10 9 cfu / g, the number of viable bacteria of Acetobacter pasteurianus is 2-6×10 8 cfu / g.

[0013] A microbial preparation, whose raw materials include, by mass: 1-2 parts of the above-mentioned microbial composition, 1-2 parts of sodium alginate, 1-2 parts of collagen, 0.08-0.24 parts of calcium chloride, 1-2 parts of glacial acetic acid, 1-3 parts of glutathione, 0.1-0.5 parts of fucoidan, 0.1-1 parts of terminal carboxyl polyamidoamine, and 0.025-0.12 parts of chitosan.

[0014] Preferably, the above-mentioned microbial preparation includes blank particles and glutathione-fucoidan-carboxyl-terminated polyamidoamine complex coated on the particles; the raw materials of the blank particles include: the above-mentioned microbial composition, sodium alginate, collagen, calcium chloride, and glacial acetic acid; and the raw materials of the glutathione-fucoidan-carboxyl-terminated polyamidoamine complex include: glutathione, fucoidan, carboxyl-terminated polyamidoamine, and chitosan.

[0015] The preparation method of the above-mentioned microbial preparation comprises the following steps: S1. Add the above-mentioned microbial composition, sodium alginate and collagen into water and stir for 1-2 hours to obtain a premixed bacterial agent; S2, adding the premixed bacterial agent to the oil phase in a stirring state and stirring for 10-30 minutes, then adding the calcium chloride aqueous solution in a stirring state, continuing to stir for 5-15 minutes after the addition is complete, adding glacial acetic acid dropwise thereto and continuing to stir for 5-10 minutes, standing at 40-45° C. for 2-4 hours, filtering, washing, and freeze-drying to obtain blank particles; S3. Add glutathione to hydrochloric acid and stir evenly, add fucoidan and terminal carboxyl polyamide amine thereto, stir at 80-90°C for 10-20 minutes, cool to room temperature, filter, wash, vacuum dry, add to chitosan aqueous solution and stir evenly, add to blank particles for coating for 10-20 minutes, and vacuum dry.

[0016] Preferably, in S2, the oil phase is at least one of palm oil, peanut oil, soybean oil, sesame oil and corn germ oil.

[0017] Preferably, in S2, the mass fraction of the calcium chloride aqueous solution is 8-12%.

[0018] Preferably, in S3, the mass fraction of the chitosan aqueous solution is 0.5-1.2%.

[0019] Beneficial effects: The present invention provides the above-mentioned Lactobacillus paracasei RBB-10, which has strong antioxidant capacity, which is much higher than that of existing strains. It can enhance the total antioxidant capacity, reduce the content of hydroxyl free radicals, superoxide anions and malondialdehyde in serum, and increase the activity of glutathione peroxidase and catalase in serum, thereby improving the body's immunity.

[0020] The applicant has found that the combination of Lactobacillus paracasei RBB-10 with Saccharomyces cerevisiae S-16 and Acetobacter pasteurianus exhibits good synergistic behavior, so that the obtained microbial composition can colonize in the intestine and exert extremely strong antioxidant activity in the body.

[0021] The microbial preparation obtained by the present invention is not only conducive to the loading of the microbial composition, but also can be compounded with sodium alginate and collagen to effectively promote the uniform dispersion of the microbial composition to form an oil-in-water emulsion, and then the microsphere structure obtained by calcium ion solidification is stable and has high mechanical strength. Glacial acetic acid is added thereto to promote the dissociation of calcium ions and the formation of gel with collagen, which effectively coats the microsphere structure and has high embedding efficiency. However, under acidic conditions, calcium ions are easily replaced and the stability decreases. The present application further coats the surface, glutathione is grafted on the surface with fucoidan, and then compounded with terminal carboxyl polyamide amine, which can not only quickly diffuse into sodium alginate, but also has good biocompatibility, significantly enhances the particle density and strength, can avoid the release of bacteria due to the destruction of the gel structure, and significantly improves the stability of the internal microbial composition.

[0022] After oral administration, the microbial preparation obtained by the present invention has a high survival rate of microorganisms in the digestive system, high storage stability, and can effectively enhance the sustained release and colonization effect of the bacteria in the body. The microbial preparation obtained by the present invention not only has good tolerance to high bile salts, but also has a high survival rate of strains in artificial gastric juice and intestinal juice, good antioxidant activity, and effectively improves the body's immunity. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1This is a photo of the colony morphology of Lactobacillus paracasei RBB-10.

[0024] Figure 2 This is a microscopic photo of Lactobacillus paracasei RBB-10.

[0025] Figure 3 This is the curve of the survival rate of Lactobacillus paracasei RBB-10 changing with pH value.

[0026] Figure 4 This is the bile salt tolerance curve of Lactobacillus paracasei RBB-10.

[0027] Figure 5 This is a graph showing the changes in intestinal microbial community genus level in the normal control group, aging model group, and RBB-10 treatment group.

[0028] Figure 6 This is a comparison of HE staining of mouse tissue sections in the normal control group, aging model group, and RBB-10 treatment group.

[0029] Figure 7 This is a comparison chart of the intestinal acetic acid and propionic acid contents of mice in the normal control group, aging model group, and RBB-10 treatment group.

[0030] Figure 8 This is a comparison chart of intestinal isobutyric acid and butyric acid contents in the normal control group, aging model group, and RBB-10 treatment group of mice.

[0031] Fig. 9 This is a comparison chart of the intestinal isovaleric acid and valeric acid contents of mice in the normal control group, aging model group, and RBB-10 treatment group.

[0032] Fig.10 This is a comparison chart of serum glutathione peroxidase activity and glutathione peroxidase inhibition rate in mice of the normal control group, aging model group, and RBB-10 treatment group.

[0033] Fig.11 This is a comparison chart of the superoxide anion inhibition activity and superoxide anion inhibition rate of mouse serum in the normal control group, aging model group, and RBB-10 treatment group.

[0034] Fig.12 This is a comparison chart of serum catalase activity and hydroxyl radical scavenging ability of mice in the normal control group, aging model group, and RBB-10 treatment group.

[0035] Fig.13 This is a comparison chart of the DPPH clearance rate and malondialdehyde content in the serum of mice in the normal control group, aging model group, and RBB-10 treatment group.

[0036] Fig.14It is a comparison chart of the embedding rates of the microbial preparations obtained in Example 10 and Comparative Examples 1-2.

[0037] Fig.15 This is a comparison chart of the index of the number of live bacteria in the microbial preparations obtained in Example 10 and Comparative Examples 1-2 after bile salt treatment.

[0038] Fig.16 This is a comparison chart of the survival rates of the microbial preparations obtained in Example 10 and Comparative Examples 1-2 after being treated with in vitro simulated digestive fluid.

[0039] Fig.17 This is a comparison chart of serum glutathione peroxidase activity and glutathione peroxidase inhibition rate of mice in the normal control group, aging model group, S10-FH group, D1-DY group, and D2-FH group.

[0040] Fig.18 This is a comparison chart of the inhibition of superoxide anion activity and superoxide anion inhibition rate of mouse serum in the normal control group, aging model group, S10-FH group, D1-DY group, and D2-FH group.

[0041] Fig.19 This is a comparison chart of the inhibition of superoxide anion activity and superoxide anion inhibition rate of mouse serum in the normal control group, S10-FH group, D1-DY group, and D2-FH group.

[0042] Fig. 20 This is a comparison chart of serum catalase activity and hydroxyl radical scavenging ability of mice in the normal control group, aging model group, S10-FH group, D1-DY group, and D2-FH group.

[0043] Fig.21 This is a comparison chart of serum catalase activity and hydroxyl radical scavenging ability of mice in the normal control group, S10-FH group, D1-DY group, and D2-FH group.

[0044] Fig. 22 This is a comparison chart of serum DPPH clearance rate and malondialdehyde content in mice of normal control group, aging model group, S10-FH group, D1-DY group, and D2-FH group. DETAILED DESCRIPTION

[0045] The present invention will be further explained below in conjunction with specific embodiments.

[0046] The following Saccharomyces cerevisiae was used ( Saccharomyces cerevisiae ) The deposit number of S-16 is CGMCC NO.30469, which is isolated by the applicant (Hangzhou Junwu Xiyan Biotechnology Co., Ltd.).

[0047] The following Acetobacter pasteurianus ( Acetobacter pasteurianus) with a deposit number of CGMCC NO.1.3001, purchased from the General Microbiology Center of China Microbiological Culture Collection Administration.

[0048] Example 1: The strain was isolated and collected by Huang Dasheng from homemade fermentation broth in Shangcheng District, Hangzhou City, Zhejiang Province, China in December 2023.

[0049] Isolation and purification of strains: Pipette 100 μL of the well-mixed fermentation broth and add it to an EP tube containing 900 μL of sterile water. -4 , 10 -5 Perform plate spreading (MRS) and culture inverted in a 37°C anaerobic incubator for 48-72 hours.

[0050] Observe the bacterial growth on the plate. After the colonies grow, pick a typical single colony and streak it on MRS solid medium for strain isolation and purification. Inoculate the single colony into 5 mL of sterilized MRS broth medium, incubate at 37°C for 48 hours, and then store it in a -80°C refrigerator with 50% glycerol for later use.

[0051] The isolated strains were identified by morphology (colony morphology such as Figure 1 As shown, the microscopic morphology Figure 2 as shown).

[0052] The isolated and purified single colonies were sent to Zhejiang Shangya Biotechnology Co., Ltd. for sequencing identification. The primers are as follows: 27F: 5'-AGAGTTTGATCMTGGCTCAG-3'; 1492R: 5'-GGTTACCTTGTTACGACTT-3'.

[0053] Its ITS / 16s sequence is as follows: The BLAST program in NCBI was used to compare the RBB-10 sequence, and the results showed that the strain was Lactobacillus paracasei, and its homology with the known Lactobacillus paracasei in the GeneBank database reached 100%, and it was named Lactobacillus paracasei ( Lacticaseibacillus paracasei )RBB-10.

[0054] Lactobacillus paracasei RBB-10 was deposited in the General Microbiology Center of China Culture Collection Administration (Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing) on ​​May 11, 2024, with the deposit number CGMCC NO.30557.

[0055] Example 2 Effect of different pH on strain survival rate Lactobacillus paracasei RBB-10 was inoculated at a 2% inoculation rate into MRS culture medium with initial pH=3.0, pH=4.0, pH=5.0, pH=6.0, and pH=7.0, respectively. After anaerobic culture at 37°C for 24 h, the OD value of the strain in the culture medium with different initial pH values ​​was measured at a wavelength of 600 nm to analyze its tolerance level.

[0056] like Figure 3 As shown in the figure, with the increase of pH, the reproduction ability of Lactobacillus paracasei RBB-10 first increased and then decreased, and the environment of pH=5 was most suitable for the reproduction and growth of Lactobacillus paracasei RBB-10.

[0057] Example 3 Effects of different bile salt concentrations on the bile salt tolerance of strains Add 0.2% ( w / v ) sodium thioglycolate, and then continue to add 0%, 0.03%, 0.1%, 0.2%, 0.3% ( w / v ) was added with bile salt No. 3 to adjust the pH to 7.2, and MRS liquid culture medium without bile salt was used as a control.

[0058] The suspension of Lactobacillus paracasei RBB-10 was diluted to 2% ( v / v ) were added to MRS liquid culture medium containing different bile salt concentrations, and three parallel replicate groups were set up and placed in anaerobic culture at 37°C for 24 hours. MRS liquid culture medium was used as a blank control, and the OD value of the strain in the culture medium with different bile salt concentrations was measured at a wavelength of 600nm to analyze the tolerance level and calculate the bile salt tolerance ability.

[0059]

[0060] Among them, A1 is the OD value of the medium containing bile salts, and A0 is the OD value of the medium without bile salts.

[0061] like Figure 4 As shown, Lactobacillus paracasei RBB-10 has a weak tolerance to bile salts. As the bile salt concentration increases, the growth and reproduction ability of Lactobacillus paracasei RBB-10 weakens.

[0062] Example 4 Detection of DPPH clearance rate Lactobacillus paracasei RBB-10 was inoculated into MRS medium at a 2% inoculum volume, and after culturing at 37°C for a certain period of time, the bacteria were taken out and washed by centrifugation. 600 The value was adjusted to 1.0, and the culture was re-inoculated into MRS medium at a 2% inoculum and cultured at 37°C for 24 hours. The cultured bacterial solution was centrifuged at 12000 r / min for 5 minutes, and then the supernatant was obtained using a 0.22 μm bacterial filter.

[0063] Then, 1 mL of the supernatant was gently aspirated using a pipette, and 1 mL of 0.02 mmol / L DPPH solution was added. The mixture was reacted for 30 min in the dark, centrifuged at 4000 rpm for 10 min, and 200 μL was taken to measure the absorbance at 517 nm.

[0064]

[0065] Among them, A i is the absorbance of 1mL DPPH + 1mL sample, A j is the absorbance of 1mL PBS + 1mL sample, A c It is the absorbance of 1mL DPPH + 1mL PBS.

[0066] The DPPH scavenging rate of the supernatant of Lactobacillus paracasei RBB-10 reached 98.0122±0.4045%, indicating that the supernatant of Lactobacillus paracasei RBB-10 has excellent antioxidant capacity.

[0067] Example 5 Detection of total antioxidant capacity (total T-AOC) Take an appropriate amount of the supernatant obtained in Example 4 and determine the total T-AOC according to the instructions of the kit (Nanjing Jiancheng Bioengineering Institute, catalog number: A015-3-1).

[0068] OD of the supernatant of Lactobacillus paracasei RBB-10 593 was 1.357, while the OD of the suspension of Lactobacillus paracasei RBB-10 was 593 is 0.118, that is, OD 593 The total value is 1.475. According to the FeSO4 standard curve, it can be concluded that the total antioxidant capacity of Lactobacillus paracasei RBB-10 is 4.51nM.

[0069] Example 6: Eight 12-week-old male C57BL6 mice were taken as a normal control group (CK), and 16 40-week-old male C57BL6 mice were randomly divided into two groups, namely, an aging model group (MC) and an RBB-10 treatment group.

[0070] Each group of experimental animals had 4 animals per cage, room temperature was 23-25℃, humidity was 40-45%, light was on for 12h per day, food and water were freely available, and bedding was changed regularly. The mice were adaptively fed for 1 week, and the intervention lasted for 14 weeks (98 days).

[0071] The groups and interventions are shown in Table 1: Table 1 Intervention treatments in the normal control group, aging model group and RBB-10 treatment group Group Experimental treatment Normal control group Basic feed + intragastric administration of normal saline 0.2mL / kg body weight Aging model group Basic feed + intragastric administration of normal saline 0.2mL / kg body weight RBB-10 treatment group <![CDATA[Basal diet + intragastric administration of Lactobacillus paracasei RBB-10 (1×10 9 cfu / kg body weight)]]>

[0072] Among them, the basic feed includes: 25% bran, 20% flour, 20% corn, 20% soybean feed, 10% rice flour, 2.5% fish meal, and 2.5% bone meal.

[0073] One day before the end of the experiment, collect 3-5 pieces of mouse feces and fast the mice for less than 12 hours. Then store the collected feces at -80℃ and send them for 16S rRNA gene high-throughput sequencing to analyze the structure of mouse intestinal flora.

[0074] After the experiment, the colon of the mice was collected and the colon was sliced ​​and observed by H&E staining; the contents of the mouse cecum were collected to determine the level of short-chain fatty acids (SCFAs). The blood of the mice was collected and temporarily stored in EDTA-K tubes to determine the glutathione peroxidase activity, glutathione peroxidase inhibition rate, catalase activity, superoxide anion inhibition activity, malondialdehyde content and hydroxyl free radical scavenging ability in the serum.

[0075] 16S rRNA gene amplicon sequencing was used to analyze the effect of oral administration of Lactobacillus paracasei RBB-10 on the composition of intestinal flora in mice. Figure 5 As shown, compared with the normal control group (CK), the beneficial bacteria in the intestine of the aging model group (MC) mice - Bifidobacterium ( Bifidobacterium ) abundance decreased, and the beneficial bacteria genus Rhabditiformis ( Muribaculum ) also decreased in abundance, while the harmful genus Helicobacter ( Helicobacter ) abundance increased.

[0076] In the RBB-10-treated group, the intestinal tract of mice contained unclassified members of the family Rhizobacteriaceae ( Unclassified Muribaculaceae ) and Rhabditis spp. Muribaculum ) abundance increased significantly. In related studies, members of the family Rhabditiaceae ( Muribaculaceae ) consumes N-acetylglucosamine and hinders the colonization of harmful intestinal bacteria, Clostridium perfringens, in the intestine, thereby reducing the occurrence of colitis and related tumors. In another study, it was shown that members of the family Rhabditiaceae in the intestine ( Muribaculaceae ) abundance, which helps improve bone health.

[0077] At the same time, the RBB-10 treatment group also significantly increased the Bifidobacterium genus ( Bifidobacterium ) and reduce the abundance of harmful bacteria, Helicobacter spp. Helicobacter ) abundance. Bifidobacterium members can produce SCFAs, which can reduce inflammation, relieve constipation, inhibit fat accumulation, and regulate sugar and lipid metabolism.

[0078] The above results and analysis all indicate that oral administration of Lactobacillus paracasei RBB-10 can increase the abundance of beneficial bacteria in the intestine, inhibit the abundance of harmful bacteria, reduce the risk of pathogenicity, improve intestinal health homeostasis, and play a positive role in the intestinal health of the elderly.

[0079] "Aging begins in the intestines." During the aging process, excessive free radicals accelerate the aging of intestinal epithelial cells, increase the permeability of the intestinal wall, and reduce the barrier function.

[0080] like Figure 6 As shown in the figure, the colon mucosal layer structure of the normal control group (CK) mice was intact, the crypts were regular and a large number of goblet cells were visible, the crypt base was intact, the structure was normal, and there was no infiltration of inflammatory cells in the mucosal layer and muscular layer. However, the aging model group (MC) showed that the mucosal layer structure was damaged, the crypts disappeared, the goblet cells decreased, and a large number of inflammatory cells infiltrated in the mucosal layer, muscular layer, and crypt base.

[0081] Compared with the aging model group (MC), the RBB-10-treated group (RBB-10) restored the complete mucosal layer structure, with regular and flat crypts, increased goblet cells, and disappeared inflammatory cells in the mucosal layer, muscularis, and crypt base. This shows that oral administration of Lactobacillus paracasei RBB-10 can improve the intestinal state of aging mice and restore the intestine to a youthful state.

[0082] Short-chain fatty acids are beneficial metabolites of the intestinal microbiota, and play a key role in regulating the host metabolic immune system and cell proliferation, promoting intestinal water and sodium absorption, lowering blood lipids and blood sugar.

[0083] The applicant analyzed the SCFAs in the cecal contents of mice by GC-MS. Figures 7 to 9As shown in the figure, compared with the normal control group (CK), the content of SCFAs (acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid and valeric acid) in the cecal contents of mice in the aging model group (MC) was significantly reduced. Compared with the aging model group (MC), the content of SCFAs in the cecal contents of mice in the RBB-10 treatment group increased significantly, and returned to the level of SCFAs in the cecal contents of young mice. This shows that the intestinal flora can be intervened by gavage of RBB-10 bacterial solution, thereby affecting the content of SCFAs, thereby providing therapeutic strategies and directions for delaying aging, regulating metabolism and immunity, and lowering blood lipids and blood sugar.

[0084] like Figures 10 to 13 As shown, the serum glutathione peroxidase activity and glutathione peroxidase inhibition rate of mice in RBB-10 treatment group were higher than those in the normal control group and the aging model group, the serum superoxide anion inhibition activity and superoxide anion inhibition rate of mice in RBB-10 treatment group were higher than those in the normal control group and the aging model group, the serum catalase activity and hydroxyl free radical scavenging ability of mice in RBB-10 treatment group were higher than those in the normal control group and the aging model group, while the serum malondialdehyde content of mice in RBB-10 treatment group was lower than that in the normal control group and the aging model group, indicating that although the mice in RBB-10 treatment group were older, oral administration of Lactobacillus paracasei RBB-10 could effectively improve the antioxidant capacity of mice and restore their antioxidant capacity to at least the level of the normal control group.

[0085] Embodiment 7: A microbial composition, comprising: the above-mentioned Lactobacillus paracasei RBB-10, Saccharomyces cerevisiae S-16, and Acetobacter pasteurianus.

[0086] In the microbial composition, the number of viable bacteria of Lactobacillus paracasei RBB-10 is 3×10 9 cfu / g, the number of viable bacteria of Saccharomyces cerevisiae S-16 was 2×10 9 cfu / g, the number of viable bacteria of Acetobacter pasteurianus is 4×10 8 cfu / g.

[0087] Example 8: A method for preparing a microbial preparation, comprising the following steps:

[0088] S1. Add 1 g of the microbial composition obtained in Example 7, 1 g of sodium alginate, and 1 g of collagen to 15 g of water, and stir at a speed of 100 r / min for 1 h to obtain a premixed bacterial agent; S2, adding the premixed bacterial agent to 50g corn germ oil in a stirring state and stirring for 10min at a stirring speed of 1000r / min, adding 1g of 8% calcium chloride aqueous solution in a stirring state, continuing to stir for 5min after the addition is complete, adding 1g of glacial acetic acid dropwise thereto, continuing to stir for 5min, standing at a temperature of 40°C for 2h, filtering, washing, and freeze-drying to obtain blank particles; S3. Add 1g of glutathione to 10g of hydrochloric acid with a pH value of 5.2-5.6 and stir evenly. Add 0.1g of fucoidan and 0.1g of 0.5-generation carboxyl-terminated polyamide amine, stir at 80°C for 10min, cool to room temperature, filter, wash, and vacuum dry. Add to 5g of 0.5% chitosan aqueous solution and stir evenly. Add to the blank particles for coating for 10min and vacuum dry.

[0089] Example 9: A method for preparing a microbial preparation, comprising the following steps:

[0090] S1. Add 2 g of the microbial composition obtained in Example 7, 2 g of sodium alginate, and 2 g of collagen to 30 g of water, and stir at a speed of 200 r / min for 2 h to obtain a premixed bacterial agent; S2, adding the premixed bacterial agent to 100g soybean oil in a stirring state and stirring for 30min at a stirring speed of 2000r / min, adding 2g of 12% calcium chloride aqueous solution in a stirring state, stirring for 15min after the addition is complete, adding 2g of glacial acetic acid dropwise thereto, stirring for 10min, standing at a temperature of 45°C for 4h, filtering, washing, and freeze-drying to obtain blank particles; S3. Add 3g of glutathione to 30g of hydrochloric acid with a pH value of 5.2-5.6 and stir evenly. Add 0.5g of fucoidan and 0.8g of 1.5-generation carboxyl-terminated polyamide amine, stir at 90°C for 20min, cool to room temperature, filter, wash, and vacuum dry. Add to 10g of chitosan aqueous solution with a mass fraction of 1.2%, stir evenly, add to the blank particles for coating for 20min, and vacuum dry.

[0091] Embodiment 10: A method for preparing a microbial preparation, comprising the following steps: S1. Add 1.5 g of the microbial composition obtained in Example 7, 1.5 g of sodium alginate, and 1.5 g of collagen to 25.5 g of water, and stir at a speed of 150 r / min for 90 min to obtain a premixed bacterial agent; S2, add the premixed bacterial agent to 80g palm oil in a stirring state and stir for 15min at a stirring speed of 1500r / min, add 1.5g of 10% calcium chloride aqueous solution in a stirring state, continue stirring for 10min after the addition is complete, add 1.5g of glacial acetic acid dropwise thereto, continue stirring for 8min, let stand at a temperature of 42°C for 3h, filter, wash, and freeze-dry to obtain blank particles; S3. Add 2g of glutathione to 20g of hydrochloric acid with a pH value of 5.2-5.6 and stir evenly. Add 0.3g of fucoidan and 0.2g of 1.0 generation carboxyl-terminated polyamidoamine thereto, stir at 85°C for 15min, cool to room temperature, filter, wash, and vacuum dry. Add to 8g of 1% chitosan aqueous solution and stir evenly. Add to the blank particles for coating for 15min and vacuum dry.

[0092] Comparative Example 1: A method for preparing a microbial preparation, comprising the following steps: S1, 1.5g of viable bacteria count is 3×10 9 cfu / g of Lactobacillus paracasei RBB-10, 1.5g of sodium alginate, and 1.5g of collagen were added to 25.5g of water, and stirred at a speed of 150r / min for 90min to obtain a premixed bacterial agent; S2, add the premixed bacterial agent to 80g palm oil in a stirring state and stir for 15min at a stirring speed of 1500r / min, add 1.5g of 10% calcium chloride aqueous solution in a stirring state, continue stirring for 10min after the addition is complete, add 1.5g of glacial acetic acid dropwise thereto, continue stirring for 8min, let stand at a temperature of 42°C for 3h, filter, wash, and freeze-dry to obtain blank particles; S3. Add 2g of glutathione to 20g of hydrochloric acid with a pH value of 5.2-5.6 and stir evenly. Add 0.3g of fucoidan and 0.2g of 1.0 generation carboxyl-terminated polyamidoamine thereto, stir at 85°C for 15min, cool to room temperature, filter, wash, and vacuum dry. Add to 8g of 1% chitosan aqueous solution and stir evenly. Add to the blank particles for coating for 15min and vacuum dry.

[0093] Comparative Example 2: A method for preparing a microbial preparation, comprising the following steps: S1. Add 1.5 g of the microbial composition obtained in Example 7, 1.5 g of sodium alginate, and 1.5 g of collagen to 25.5 g of water, and stir at a speed of 150 r / min for 90 min to obtain a premixed bacterial agent; S2. Add the premixed bacterial agent to 80g of palm oil in a stirring state and stir for 15 minutes at a stirring speed of 1500r / min. Add 1.5g of 10% calcium chloride aqueous solution in a stirring state. After the addition is complete, continue stirring for 10 minutes. Add 1.5g of glacial acetic acid dropwise and continue stirring for 8 minutes. Let stand at 42°C for 3h, filter, wash, and freeze-dry.

[0094] The microbial preparations obtained in Example 10 and Comparative Examples 1-2 were used for comparative experiments, as follows:

[0095] 1. Determination of embedding rate: Add 1 g of each microbial preparation to an appropriate amount of 0.06 mol / L sodium citrate solution, mix, and shake at 180 r / min in a constant temperature shaker at 37°C for 60 min. Count the live Lactobacillus paracasei RBB-10 in each group and calculate the embedding rate.

[0096]

[0097] Wherein, N is the number of live Lactobacillus paracasei RBB-10 released from the microbial preparation; N0 is the number of free Lactobacillus paracasei RBB-10 in the mixture during the production of the microbial preparation.

[0098] like Fig.14 As shown, the embedding rate of the microbial preparation obtained in Comparative Example 2 is the highest. However, the embedding rates of the microbial preparations obtained in Example 10 and Comparative Example 1 are lower, and there is no significant difference (P>0.05).

[0099] 2. Bile salt tolerance test: The concentration of Lactobacillus paracasei RBB-10 in each group of microbial preparations was 1×10 10 cfu / g) was inoculated into MRS liquid medium with a bile salt concentration of 0.3% (w / v) at a volume fraction of 10%, and then placed in a 37°C incubator for 4 hours. Then, an appropriate amount of 0.06 mol / L sodium citrate solution was added and mixed, and the mixture was shaken at a speed of 180 r / min for 60 minutes in a 37°C constant temperature shaker, and the live Lactobacillus paracasei RBB-10 in each group was counted.

[0100] like Fig.15 As shown, the microbial preparations obtained in Example 10 and Comparative Example 1 still maintained high activity after bile salt treatment, but there was no significant difference between the two (P>0.05). However, after the microbial preparation obtained in Comparative Example 2 was treated with bile salt, the number of live Lactobacillus paracasei RBB-10 decreased significantly.

[0101] 3. In vitro simulated digestive fluid tolerance test: The simulated gastric fluid used was as follows: 1 mol / L hydrochloric acid was used to adjust the pH value of 0.5% NaCl solution to 2.0, pepsin was added to make the final concentration of the enzyme in the solution 3.0 g / L, and then filtered and sterilized using a 0.22 μm aqueous phase filter membrane.

[0102] The simulated intestinal fluid used was as follows: Trypsin, bile salts and phenol were added to 0.5% NaCl solution to make them evenly dispersed, and the final concentrations were 1.0 g / L, 5.0 g / L and 4.0 g / L, respectively. The pH value of the system was adjusted to 8.0 with 1 mol / L NaOH solution, and then filtered and sterilized with a 0.22 μm aqueous phase filter membrane.

[0103] Take 1g of each group of microbial preparations, add to 9mL of simulated gastric fluid, shake and mix the microcapsules and artificial gastric fluid evenly, then shake at 160r / min in a constant temperature shaker at 37±1℃, centrifuge after 180min to discard the simulated gastric fluid, add 9mL of simulated intestinal fluid, shake and mix the remaining microbial preparations and artificial intestinal fluid evenly, then shake at 160r / min in a constant temperature shaker at 37±1℃, and count after 420min.

[0104] For counting, the remaining microbial preparation was washed with physiological saline, dissolved in 9 mL of 0.06 mol / L sodium citrate solution, and after gradient dilution, the live bacteria were counted using the spread plate method.

[0105]

[0106] Among them, A1 is the number of Lactobacillus paracasei RBB-10 cells during the test, cfu / g; A0 is the number of Lactobacillus paracasei RBB-10 cells at the beginning of digestion, cfu / g.

[0107] like Fig.16 As shown, the microbial preparations obtained in Example 10 and Comparative Example 1 still maintained high activity after being treated with simulated digestive fluid, but there was no significant difference between the two (P>0.05). However, after the microbial preparation obtained in Comparative Example 2 was treated with digestive fluid, the number of live Lactobacillus paracasei RBB-10 decreased significantly.

[0108] 4. Antioxidant effect in aged mice: 24 40-week-old male C57BL6 mice were randomly divided into 3 groups, namely S10-FH group, D1-DY group and D2-FH group, with 4 experimental animals / cage in each group, room temperature 23-25℃, humidity 40-45%, 12h light per day, free access to food and water, regular replacement of bedding, and gavage once a day at a fixed time. The mice were adaptively fed for 1 week and intervened for 14 weeks (98d).

[0109] The groups and interventions are shown in Table 2: Table 2 Intervention treatments in the S10-FH, D1-DY, and D2-FH groups Group Experimental treatment S10-FH group Basic feed + 0.5g of the microbial preparation obtained in Example 10 D1-DY group Basic feed + 0.5g microbial preparation obtained in comparative example 1 D2-FH group Basic feed + 0.5g of the microbial preparation obtained in Comparative Example 2

[0110] Wherein, the basic feed is the same as that in Example 6.

[0111] The normal control group and the aging model group continued to use the data in Example 6 above.

[0112] like Fig.17 , Fig.18 , Fig. 20 and Fig. 22 As shown, serum glutathione peroxidase activity and glutathione peroxidase inhibition rate of mice in S10-FH group, D1-DY group and D2-FH group were higher than those in normal control group and aging model group, serum superoxide anion inhibition activity and superoxide anion inhibition rate of mice in S10-FH group, D1-DY group and D2-FH group were higher than those in normal control group and aging model group, serum catalase activity and hydroxyl free radical scavenging ability of mice in S10-FH group, D1-DY group and D2-FH group were higher than those in normal control group and aging model group, while serum malondialdehyde content of mice in S10-FH group, D1-DY group and D2-FH group was lower than that in normal control group and aging model group. This indicates that although the mice in S10-FH group, D1-DY group and D2-FH group were older, oral administration of microbial preparations can effectively improve the antioxidant capacity of mice.

[0113] like Fig.17 , Fig.19 , Fig.21 and Fig. 22 As shown, the serum glutathione peroxidase activity and glutathione peroxidase inhibition rate of mice in S10-FH group were higher than those in D1-DY group and D2-FH group, the serum superoxide anion inhibition activity and superoxide anion inhibition rate of mice in S10-FH group were higher than those in D1-DY group and D2-FH group, the serum catalase activity and hydroxyl radical scavenging ability of mice in S10-FH group were higher than those in D1-DY group and D2-FH group, while the serum malondialdehyde content of mice in S10-FH group was lower than that in D1-DY group and D2-FH group, which confirmed that the microbial preparation obtained by oral administration of Example 10 can more effectively improve the antioxidant capacity of mice, and also confirmed that the combination of Lactobacillus paracasei RBB-10 with Saccharomyces cerevisiae S-16 and Acetobacter pasteurianus can better enhance the antioxidant capacity of mice.

[0114] The serum antioxidant indices of mice in the D1-DY group were compared with those in the Mle-3 treatment group in Example 6, and it was found that the serum antioxidant indices of mice in the D1-DY group were significantly better than those in the Mle-3 treatment group. This indicates that the use of microbial preparations can effectively help the microbial composition (especially Lactobacillus paracasei RBB-10) pass through the digestive juice, which is beneficial to the colonization of the microbial composition in the intestine and improves the body's antioxidant capacity.

[0115] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. Lactobacillus paracasei ( Lacticaseibacillus paracasei )RBB-10 is used in any of the following (1)-(5): (1) Preparation of antioxidant products; (2) Preparation of anti-aging products; (3) preparing products for repairing colon mucosa; (4) Preparation of Helicobacter spp. Helicobacter ) products grown; (5) Preparation of unclassified members of the family Rhabditiaceae that promote intestinal Unclassified Muribaculaceae ), Rhabditis spp. Muribaculum ) or / and Bifidobacterium spp. ( Bifidobacterium ) products grown.

2. The use according to claim 1, It is characterized in that Lactobacillus paracasei RBB-10 was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration with the deposit number of CGMCC NO.30557.

3. The use according to claim 1, It is characterized in that The products are microbial preparations, health foods or medicines.

4. A microbial composition, It is characterized in that include: The Lactobacillus paracasei RBB-10 used in claim 1.

5. The microbial composition according to claim 4, It is characterized in that Also includes: Saccharomyces cerevisiae Saccharomyces cerevisiae ) S-16, Acetobacter pasteurianus ( Acetobacter pasteurianus ); Among them, the viable count of Lactobacillus paracasei RBB-10 was 1-5×10 9 cfu / g, the number of viable bacteria of Saccharomyces cerevisiae S-16 is 1-3×10 9 cfu / g, the number of viable bacteria of Acetobacter pasteurianus is 2-6×10 8 cfu / g.

6. A microbial preparation, It is characterized in that The raw materials include, by mass, 1-2 parts of the microbial composition as claimed in claim 4 or 5, 1-2 parts of sodium alginate, 1-2 parts of collagen, 0.08-0.24 parts of calcium chloride, 1-2 parts of glacial acetic acid, 1-3 parts of glutathione, 0.1-0.5 parts of fucoidan, 0.1-1 parts of terminal carboxyl polyamidoamine, and 0.025-0.12 parts of chitosan.

7. The microbial preparation according to claim 6, It is characterized in that It includes blank particles and a glutathione-fucoidan-carboxyl-terminated polyamidoamine complex coated on the particles; The raw materials of the blank particles include: the microbial composition as claimed in claim 4 or 5, sodium alginate, collagen, calcium chloride, and glacial acetic acid; The raw materials of the glutathione-fucoidan-carboxyl-terminated polyamidoamine complex include: glutathione, fucoidan, carboxyl-terminated polyamidoamine and chitosan.

8. A method for preparing the microbial preparation according to claim 6 or 7, It is characterized in that The steps include: S1. Add the microbial composition as claimed in claim 4 or 5, sodium alginate and collagen into water and stir for 1-2 hours to obtain a premixed bacterial agent; S2, adding the premixed bacterial agent to the oil phase in a stirring state and stirring for 10-30 minutes, then adding the calcium chloride aqueous solution in a stirring state, continuing to stir for 5-15 minutes after the addition is complete, adding glacial acetic acid dropwise thereto and continuing to stir for 5-10 minutes, standing at 40-45° C. for 2-4 hours, filtering, washing, and freeze-drying to obtain blank particles; S3. Add glutathione to hydrochloric acid and stir evenly, add fucoidan and terminal carboxyl polyamide amine thereto, stir at 80-90°C for 10-20 minutes, cool to room temperature, filter, wash, vacuum dry, add to chitosan aqueous solution and stir evenly, add to blank particles for coating for 10-20 minutes, and vacuum dry.

9. The method for preparing the microbial preparation according to claim 8, It is characterized in that In S2, the oil phase is at least one of palm oil, peanut oil, soybean oil, sesame oil, and corn germ oil.

10. The method for preparing the microbial preparation according to claim 8, It is characterized in that In S2, the mass fraction of the calcium chloride aqueous solution is 8-12%; in S3, the mass fraction of the chitosan aqueous solution is 0.5-1.2%.

Citation Information

Patent Citations

  • Chitosan derivative with mucosal adhesion and Pept-1 targeting performance and preparation method thereof

    CN107903337A

  • Lactobacillus paracasei ET-22 capable of adjusting balance of microbial populations in intestinal tracts

    CN110964653A

  • Lactobacillus paracasei Lc19 and microbial preparation containing lactobacillus paracasei Lc19

    CN113201467A

  • Application of lactobacillus paracasei ET-22 in promotion of bone health

    CN113230281A

  • Lactobacillus paracasei ET-22 for resisting oxidation and regulating blood pressure and application of lactobacillus paracasei ET-22

    CN113349254A

Cited By

  • Lactobacillus paracasei SX-G1520 and application of lactobacillus paracasei SX-G1520 in preparation of lipid-lowering, anti-inflammatory and / or antioxidant products

    CN119799600A